Boston, MA 02203
$Conference + 2 Workshops USD 2697.00, Conference + 1 Workshop USD 2348.00, Conference Only USD 1999.00
Lectures & Conferences
The Biomarkers for Alzheimer’s Disease Summit is the industry’s only digital forum dedicated to sharing innovations in identifying new novel biomarkers and solving the challenges of developing clinically validated biomarkers for the earlier detection and diagnosis of Alzheimer’s Disease that are predictive of outcome measures and accurately reflect a therapeutic effect on target engagement!
Back for its 2nd year there will be a continued emphasis on looking beyond amyloid and tau and diversifying the biomarker landscape, this industry-defining meeting delves into blood-based biomarkers, neuroinflammatory markers and ample sharing of industry innovations in identifying novel biomarkers. Through open reflections and sharing competitive knowledge, this meeting will enable drug developers to scale the hurdles preventing the identification and validation of biomarkers to accelerate the development of disease modifying therapeutics for Alzheimer’s including:
Utilizing Animal Models & Their Translational Models
Advancements in Patient Stratification & Identification
Updates in Neurodegenerative Disease Modelling
Presenting Biomarker Efficacy & Clinical Validation
For the full program, download the brochure here!
The Biomarkers for Alzheimer’s Disease Summit is your opportunity to discuss in-depth the cutting-edge advances in biomarker science, convey lessons learned and network to build long lasting partnerships.
Speakers: Michael Fossel, President & Founder, Telocyte, Andreas Jeromin, Chief Scientific Officer, Cohen Veterans Bioscience, Chris Whelan, Associate Director & Head of Translational Genetics, Biogen, Leslie Holsinger, Executive Vice President of Research & Development, Cortexyme, Michela Gallagher, Founder & Chief Executive Officer, AgeneBio, Sharon Rosenzweig-Lipson, Vice President of Research & Development, AgeneBio, CJ Barnum, Head of Neuroscience, INmune Bio, Hans Moebius, Chief Medical Officer, Athira Pharma, Juli Jones, Director & Head of Disease Biology, Cyclerion Therapeutics, Chrisopher Winrow, Head of Translational Medicine, Cyclerion Therapeutics, Michele Vendruscolo, Chief Scientific Officer, Wren Therapeutics, Jonathan Levenson, Vice President of Translational Biology, Tiaki Therapeutics, Stan Chamberlain, Chief Scientific Officer, T3D Therapeutics, Felix Yeh, Head of Biomarkers, Alector, Mark Frasier, Co-Chief Scientific Officer, The Michael J Fox Foundation, Nicole Bjorklund, Assistant Director – Scientific Affairs, Alzheimer’s Drug Discover Foundation, Ralph Kern, President & Chief Medical Officer, BrainStorm Cell Therapeutics, Stacy Lindborg, Executive Vice President & Head of Global Clinical Research, BrainStorm Cell Therapeutics, Douglas Galasko, Associate Director, UCSD Shiley-Marcos Alzheimer’s Disease Research Center, Elizabeth Somers, Director of Diagnostic Development & Translational Medicine Diagnostic Development, Translational Medicine & Diagnostics Eisai, Maria Maccecchini, Founder, President, CEO and Executive Board Member, Annovis Bio